Recurrence score test for ovarian cancer using exosomes
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study is testing a new way to predict if ovarian cancer will come back after treatment. By looking at tiny particles called exosomes in your blood, researchers hope to create a score that can guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with epithelial ovarian cancer that has come back (recurred) after treatment.
- Your cancer responded well to your last platinum-based chemotherapy and you had at least 6 months without treatment before it returned.
- You have had no more than 2 prior lines of therapy for your cancer (maintenance therapy doesn't count).
- You are in generally good health (ECOG performance status 0 to 2) and expected to live at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test to look at tiny particles called exosomes to predict if ovarian cancer might come back. If you have been diagnosed with epithelial ovarian cancer in the last 8 weeks and haven't started treatment yet, this study could help you.
This trial tests a new blood-based test (OCS) that looks for tiny particles from tumor cells to watch for cancer returning after initial treatment. It is for women with ovarian cancer whose CA125 levels were normal before starting treatment.
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
This study is testing a new blood test that may help detect ovarian cancer earlier. Researchers want to see if it can tell the difference between people with ovarian cancer and those without it.
This study looks at tumor tissue from ovarian cancer patients to find “biomarkers,” or lab signals, that may predict how the disease behaves or how it might respond to treatment. You may be asked for a biopsy of the relapsed (coming back) tumor or to use an existing archived tumor sample.
This laboratory study uses ovarian cancer fluid collected during surgery to test possible new treatments on cancer and immune cells. It may help researchers find better treatment options in ovarian cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.